|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM224126741 |
| 003 |
DE-627 |
| 005 |
20250214205733.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2012.12.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0747.xml
|
| 035 |
|
|
|a (DE-627)NLM224126741
|
| 035 |
|
|
|a (NLM)23314272
|
| 035 |
|
|
|a (PII)S1521-6616(12)00295-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Karlsson, Ingrid
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.04.2013
|
| 500 |
|
|
|a Date Revised 04.02.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a ClinicalTrials.gov: NCT01009762
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2012 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We investigated the potential of inducing additional T-cell immunity during chronic HIV-1 infection directed to subdominant HIV-1 epitopes from common HLA-supertypes. Ten treatment-naïve HIV-1-infected individuals were immunized with peptides in the adjuvant CAF01. One individual received placebo. T-cell immunogenicity was examined longitudinally by a flow cytometry (CD107a, IFNγ, TNFα, IL-2 and/or MIP1β expression) as well as IFNγ ELISPOT. Safety was evaluated by clinical follow up combined with monitoring of biochemistry, hematology, CD4 T-cell counts and viral load. New CD4 and CD8 T-cell responses specific for one or more vaccine epitopes were induced in 10/10 vaccinees. The responses were dominated by CD107a and MIP1β expression. There were no significant changes in HIV-1 viral load or CD4 T-cell counts. Our study demonstrates that the peptide/CAF01 vaccine is safe and that it is possible to generate new HIV-1 T-cell responses to defined epitopes in treatment-naïve HIV-1-infected individuals
|
| 650 |
|
4 |
|a Clinical Trial, Phase I
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Epitopes, T-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a HLA-A Antigens
|2 NLM
|
| 650 |
|
7 |
|a HLA-B Antigens
|2 NLM
|
| 650 |
|
7 |
|a HLA-C Antigens
|2 NLM
|
| 650 |
|
7 |
|a Immunodominant Epitopes
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 700 |
1 |
|
|a Brandt, Lea
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vinner, Lasse
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kromann, Ingrid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Andreasen, Lars Vibe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Andersen, Peter
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gerstoft, Jan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kronborg, Gitte
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fomsgaard, Anders
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 146(2013), 2 vom: 15. Feb., Seite 120-30
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:146
|g year:2013
|g number:2
|g day:15
|g month:02
|g pages:120-30
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2012.12.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 146
|j 2013
|e 2
|b 15
|c 02
|h 120-30
|